Life Sciences Daily Summary
Life Sciences Daily Summary: What Happened on November 19, 2026
FDA approves Lembaz to reduce mortality risk in eligible Niemann-Pick patients
A retrospective study found that enterocolitis after CAR T therapy for multiple myeloma was active when some patients died. The day also brought another FDA approval, a proposed UK rule change, and new biotech financing and dealmaking.
Today in brief
The FDA approved Beren's Lembaz for adults and children with infantile-onset Niemann-Pick disease type C who meet weight and age-of-onset criteria.1 A multicenter study identified enterocolitis in 41 patients treated with cilta-cel for multiple myeloma. Seventeen died while the condition was active.2
Regeneron's Livsayis won FDA approval for adults with antibody-positive generalized myasthenia gravis. The UK proposed broadening its legal definition of gene therapy medicines.34 Seawolf launched with $100 million in financing and a Sanofi collaboration. AbbVie agreed to pay DISCO Pharmaceuticals $40 million upfront in a cancer drug discovery deal.56
Lembaz approved for eligible patients with Niemann-Pick disease
The FDA approved Beren's Lembaz, or adrabetadex, to reduce mortality risk in adults and children who weigh at least 7 kilograms and whose neurological symptoms began before age 6.1 In an analysis of 36 treated patients, mortality risk was 55% lower than among matched external controls.1
Diagnosing the disease can take years. Beren now needs to identify patients who may qualify for treatment.1
Study finds severe, sometimes fatal enterocolitis after cilta-cel
A multicenter retrospective study classified 41 of 53 evaluable suspected cases as immune effector cell-associated enterocolitis after ciltacabtagene autoleucel, or cilta-cel, treatment for multiple myeloma.2 Tissue testing confirmed 31 cases, while researchers considered 10 probable.2 The estimated cumulative rate was 3.0% among 1,308 cilta-cel recipients included in the incidence calculation. The authors cautioned that the referral-based estimate may not reflect the broader treated population.2
Symptoms began a median of 75 days after infusion. Of 40 patients with diarrhea, 34 had severe symptoms.2 At last follow-up, 13 patients had recovered, 11 still had symptoms, and 17 had died while enterocolitis remained active.2 A separate MD Anderson cohort found nine cases among 158 cilta-cel recipients. Affected patients had 100 times greater CAR T-cell persistence than patients without the condition.7
Livsayis wins FDA approval for antibody-positive myasthenia gravis
The FDA approved Regeneron's Livsayis for adults with generalized myasthenia gravis who test positive for anti-AChR antibodies.3 The siRNA treatment is injected under the skin four times a year. It is designed to lower circulating factor 5 and reduce terminal complement activation.3
In the Phase 3 NIMBLE trial, patients improved 4.5 points on a daily-living scale at week 24, compared with 2.2 points on placebo. The 2.3-point difference was statistically significant.3 The most common adverse reactions, each reported in at least 5% of patients, were injection-site reactions, urinary tract infections, and viral infections.3 European Union regulators are reviewing the drug, with a decision expected in late 2027.3
UK proposes broader legal definition of gene therapy medicines
The UK government proposed revising the legal definition of gene therapy medicines to bring certain synthetic therapies and genome-editing treatments into the existing advanced therapies framework.4 The government says the revision would clarify classification and regulatory requirements without changing approval standards or requiring licensed medicines to be reclassified.4
The proposal would amend the Human Medicines Regulations 2012 and requires international notification procedures and parliamentary approval.4 The consultation received support from 83% of respondents.4
Seawolf launches with $100 million and a Sanofi collaboration
Seawolf emerged from stealth with $100 million in seed and Series A financing and an upfront payment from Sanofi under a collaboration.5 Its TRIDENT platform puts therapeutic DNA and RNA, encoding a protein intended to help DNA enter the cell nucleus, into one lipid nanoparticle.5
The company aims to pair the durability of viral gene therapies with the ability to redose RNA-based lipid nanoparticles, while limiting immune responses that could prevent repeat dosing.5
AbbVie offers DISCO up to $2.5 billion for cancer discovery programs
AbbVie will pay DISCO Pharmaceuticals $40 million upfront to discover cancer drugs. DISCO could receive up to $2.5 billion more in option, development, and other milestone payments, plus tiered royalties.6 DISCO will conduct research, after which AbbVie may take exclusive licenses to selected programs.6
DISCO's platform searches for pairs of surface proteins found together more often on cancer cells than on healthy tissue.6
Johnson & Johnson agrees to buy Ollin for up to $3.325 billion
On November 16, Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront and up to $1.125 billion in regulatory and commercial milestone payments.8 Ollin's lead drug, OLN324, is an investigational bispecific antibody in Phase 3 development for retinal diseases, including wet age-related macular degeneration and diabetic macular edema.8
Johnson & Johnson also announced a $750 million development-financing arrangement with Blackstone Life Sciences, with contingent payments and royalties.8
White House withdraws Overton's FDA nomination
On November 17, the White House withdrew Heidi Overton's nomination to lead the FDA, the night before a Senate committee was scheduled to consider it.910 Three sources cited by Reuters said the nomination lacked enough congressional support. Senator Bill Cassidy said he believed Overton had enough votes to advance.910
Kyle Diamantas continues to lead the agency in an acting capacity.9 The FDA expects to finish its review of mifepristone's safety by March 2027.9
FDA approves Infilbray for neurological symptoms of Type 3 Gaucher disease
On November 18, the FDA approved Infilbray for neurological symptoms of Type 3 Gaucher disease in adults and children weighing at least 15 kilograms.11 The drug crosses the blood-brain barrier and inhibits an enzyme involved in the buildup of harmful substances.11
In a 43-person study, patients taking Infilbray improved on a combined measure of coordination and cognitive function at week 52 compared with patients receiving enzyme replacement therapy.11 Reported risks include gastrointestinal and mood effects, suicidal thoughts and behavior, possible vision clouding in younger patients, and potential fetal-development harm during pregnancy.11
California biopharma layoffs reach at least 1,176 workers
A BioSpace tally found that 24 California biopharma companies had made or projected cuts affecting at least 1,176 workers this year.12 Nine companies were cutting at least half their workforces, and two had closed.12
Among the listed cuts, Arsenal Biosciences said it would eliminate 99 positions, while Caribou Biosciences' layoff notice listed 87 jobs.12 Artiva Biotherapeutics said it would cut about 94% of its staff after stopping development of its lead candidate.12